Photographic portrait of Subin Baral
Given the need for external innovation to achieve future growth targets – and the high price tag of M&A – strategic partnerships will be key for biopharmas.

Subin Baral

Global Deals Leader, Life Sciences

Committed to helping life sciences companies create focused business models that outperform. Family-focused. Loves road trips and the outdoors.

Subin is a partner at Ernst & Young LLP, and the Global Life Sciences Deals Leader. He has more than a decade of transaction experience, helping life sciences companies on transformational transactions.

Subin has extensive global experience serving as a sell-side transaction advisor for Fortune 500 companies, including corporate and private equity. His experience includes working with companies in the pharmaceutical, medical device and biotechnology subsectors.

Subin focuses on acquisitions, carve-outs, spin-offs and initial public offerings and works with companies at all stages of maturity, from start-up to public company. He frequently speaks at life sciences events on acquisitions and divestitures topics.  

He received his Master of Commerce from Macquarie University, Sydney, Australia. He is a chartered accountant from the Institute of Chartered Accountants of Australia and New Zealand.

How Subin is building a better working world

“I am building a better working world by assisting life sciences companies of all sizes to remain agile at a time of dynamic change. By asking better questions while advising companies on how to improve their portfolios, I work alongside them to help create new opportunities for investment in high-growth areas.”

Contact Subin